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Abstract: 
Background: Dose-escalation of epertinib (S-222611), a new potent oral EGFR/HER2 
inhibitor, has established a recommended daily dose of 800 mg in patients with solid tumours. 
In this study, we have recruited a larger number of patients to assess further the safety, 
tolerability, pharmacokinetics (PK) and antitumour activity.  
Patients and methods: Patients with solid tumours expressing EGFR or HER2 received a 
single dose of epertinib at 800 mg on Day 1 to assess PK over 7 days, followed by continuous 
once-daily dosing from Day 8.  
Results: We treated 76 patients with breast (n = 27), upper gastrointestinal (GI; n = 30), head 
and neck (n = 12) or renal cancers (n = 7). Epertinib was well-tolerated with mostly Grade 1 
and 2 adverse events (AE).  The most frequent AE was diarrhoea, which was generally 
manageable with loperamide.  The objective response rate (ORR) in patients with heavily 
pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), 
respectively. All 6 responding patients had HER2-positive tumours; the ORR for HER2-
positive breast and upper GI cancer populations was 19.0% and 20.0%. Partial response in 
the brain disease of one breast cancer patient lasted 7.5 months.  
Conclusion: Once-daily dosing of epertinib at 800 mg was well-tolerated, and demonstrated 
promising antitumour activity in patients with heavily pretreated HER2-positive breast and 
upper GI cancer, including those with brain metastases.  
EudraCT Number: 2009-017817-31 
Keywords: Epertinib, S-222611, EGFR, HER2, tyrosine kinase inhibitor 
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1. Introduction 
 Human epidermal growth factor receptor 2 (HER2) is known to be overexpressed in 
approximately 25% of breast cancers and around 20% of gastric cancers, and is associated 
with poor clinical outcome [1, 2].  Trastuzumab, a monoclonal antibody that binds to the 
extracellular domain of HER2, has been established for HER2-positive breast cancer 
treatment in the metastatic and early settings, and for HER2-positive metastatic gastric cancer 
treatment [3-5].  However, in metastatic breast cancer response rates to trastuzumab are only 
15% as monotherapy and 49% in combination with paclitaxel [6, 7].  Also, eventually 
resistance develops in responding patients, and a significant incidence of cardiac toxicity 
particularly in patients previously exposed to anthracyclines has been reported [8].  Several 
aditional anti-HER2 agents, including lapatinib, neratinib, pertuzumab and ado-trastuzumab 
emtansine (T-DM1), are approved, but efficacy is still not completely satisfactory despite 
overall survival improvement with T-DM1 and pertuzumab [3, 9-13].  Therefore, there 
remains an unmet need for HER2 inhibitors that are effective and well tolerated with chronic 
administration.   
Epertinib (S-222611, Shionogi & Co. Ltd, Osaka, Japan) is an orally active, reversible, 
selective and potent inhibitor of epidermal growth factor receptor (EGFR), HER2 and HER4 
kinases. Compared with lapatinib, which has a similar mechanism of action, in mouse 
xenograft models epertinib showed more prolonged inhibition of EGFR and HER2 
phosphorylation in vitro, and 4-6 fold greater antitumour activity [14].  Superior survival was 
also observed in a brain metastasis model of breast cancer, with good penetration of the blood 
brain barrier [14].  
We previously performed a phase I dose-escalation study in 33 patients with solid 
tumours expressing EGFR and/or HER2 [15]. Oral epertinib was well tolerated at doses 
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ranging from 100 mg to 1600 mg, and a maximum tolerated dose was not reached. Drug 
exposure increased dose-proportionally over a range from 100 mg to 800 mg and tumour 
responses were observed across a range of doses. Based on these results, a dose of 800 mg 
was selected for further study. We now report an extended study of epertinib in patients with 
advanced solid tumours over-expressing EGFR and/or HER2. 
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2. Methods 
2.1. Patients 
Eligible patients were ≥ 18 years old with histologically and/or cytologically confirmed 
EGFR and/or HER2-positive adenocarcinoma of the breast, with or without cerebral 
metastases; adenocarcinoma of the stomach, gastro-esophageal junction or esophagus; renal 
cell carcinoma; or squamous cell carcinoma of the head and neck, that had progressed 
following treatment with approved therapies, or for which no standard therapy was available. 
The EGFR and HER2 expression were assessed at central or local laboratories using fresh 
tumour biopsy obtained at screening or archival tissue for confirmation of the eligibility, 
while the EGFR/HER2 status assessed by the central review was used for evaluation of 
efficacy. Eligible patients were required to have Eastern Cooperative Oncology Group 
(ECOG) performance status 0 or 1, and adequate hematological, renal, hepatic and left 
ventricular function (≥ 50%). Patients with brain metastasis from HER2-positive breast 
cancer were allowed to be enrolled in this study based on the evidence showing that superior 
efficacy in suppressing tumour growth of brain metastases compared to lapatinib in an 
intracranial implantation mouse model [14]. The study was approved after review by the 
relevant regulatory and independent ethics committees (EudraCT Number: 2009-017817-31), 
and was conducted in accordance with the Declaration of Helsinki and International 
Conference on Harmonization Good Clinical Practice. All patients provided written informed 
consent before enrollment.  
 
2.2. Study design 
Epertinib was initially administered as a single dose on Day 1, followed by continuous daily 
dosing from Day 8 to Day 28. Patients received continuous dosing with epertinib in 28-day 
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cycles until disease progression, intolerable toxicity or withdrawal of consent. The primary 
objective was to assess further the safety and tolerability of epertinib. Secondary objectives 
included pharmacokinetics (PK) and an extended assessment of efficacy. 
 
2.3. Safety assessment 
Adverse events (AEs) were monitored and clinical laboratory parameters, weight, vital signs, 
12 lead ECGs, physical and ophthalmic examinations, cardiac function including left 
ventricular ejection fraction, and ECOG performance status were assessed at baseline and 
throughout the study, and lead II continuous monitoring was carried out for 8 hours post-
dosing on Day 1. All AEs were coded using National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 
 
2.4. Pharmacokinetic analysis 
Blood samples for the measurement of plasma concentrations of epertinib and its active de-
alkylated and lactam metabolites were taken at the following times during treatment: Day 1 
(pre-dose, 2, 4, 6, and 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 (48 hours 
post-dose), Day 5 (96 hours post-dose), Days 8, 15, 22 and 29 (pre-dose). Samples were also 
taken before dosing on Days 15 and 29 of the first two cycles of Part B.  Plasma 
concentration measurement and calculation of the PK parameters of epertinib and its active 
metabolites were performed in the same manner as described in our previous report [15]. 
 
2.5. Tumour evaluation  
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Tumour response was assessed every 8 weeks according to Response Evaluation Criteria in 
Solid Tumours (RECIST) Version 1.1 [16].  Patients who had at least one additional scan 
after baseline, and patients who had no additional scan but discontinued due to clinical 
disease progression, were considered evaluable for response.  
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3. Results 
3.1. Safety and tolerability 
 Between July 2010 and January 2014, a total of 76 patients with breast (n = 27), upper 
GI (n = 30), head and neck (n = 12) and renal cell carcinoma (n = 7) were enrolled at 9 sites 
in the United Kingdom and France. Patient demographics and baseline characteristics are 
summarised in Table 1. As shown in patient disposition (Figure S1), 14 patients (7 patients in 
Part A and 7 patients in Part B) discontinued due to treatment-emergent adverse events 
(TEAEs). Only 2 patients discontinued due to TEAEs (nausea and vomiting, and bilirubin 
elevation) that were considered drug-related. Disease progression accounted for all other 
discontinuations except for one patient who was withdrawn due to deteriorating quality of life.  
Table 2 summarises all TEAEs of any grade occurring in at least 10% of patients, and all 
Grade 3 or higher TEAEs. There were no treatment-related deaths. Epertinib at 800 mg once 
daily was well tolerated by most patients, with 21.1% (16/76) of patients requiring dose 
reduction. The majority of AEs were Grade 1 or 2 in intensity, and no significant 
hematological or biochemical toxicity was observed. Overall, the most frequently reported 
AEs were diarrhoea, nausea, rash and anorexia. Diarrhoea was generally self-limiting or 
effectively controlled with loperamide; in 10 (13.2%) patients it was Grade 3. Nausea was 
almost always Grade 1 or 2 and was effectively managed with antiemetics and dose 
interruptions.  Rash was reported in 32 (42.1%) patients, of which none was more severe than 
Grade 2.  There were no effects on ECG, and no evidence that epertinib treatment affected 
cardiac function. 
Bilirubin elevation was observed in 23 patients (30.3%); this elevation was Grade 3 in 5 
patients (6.6%), and Grade ≤2 in all others. The increase in bilirubin was not associated with 
any symptoms, elevation of liver enzymes or hematologic abnormalities. When the 
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unconjugated and conjugated bilirubin was measured in 14 of the 23 patients, the elevation 
was predominantly attributable to unconjugated bilirubin. Dose reduction was required due to 
bilirubin elevation in 1 patient (1.3%), and resulted in study discontinuation in one (1.3%) 
other patient. 
 
3.2. Pharmacokinetic analysis. 
The PK parameters after single administration and trough plasma concentrations after 
repeated doses at 800 mg are summarised in Table S1. Epertinib was absorbed with a median 
Tmax of 4.1 hours and geometric mean Cmax of 454 ng/mL following a single oral dose. The 
geometric mean t1/2,z was 33.8 hours and steady-state was achieved within 7 days of 
once-daily dosing. The pharmacologically active dealkylated and lactam metabolites of 
epertinib were rapidly formed, and the exposures (AUC0-inf and Cmax) to these metabolites 
were 5-7% and 6-8% on a molecular basis of the parent epertinib, respectively.  
 
3.3. Clinical response. 
Sixty five of 76 patients were evaluable for tumour response. The tumour responses for each 
cancer are shown in Table S2. Two patients with gastro-esophageal junction tumours had CR 
and PR, and 4 patients with breast cancer experienced PR. The objective response rate (ORR) 
for breast, upper GI, head and neck and renal cell cancers were 16.0% (4/25), 8.3% (2/24), 
0% (0/9) and 0% (0/7), respectively.  As shown in Table 3, all of the 4 responding breast 
cancer patients were HER2-positive, but 2 of them were EGFR-negative. All 4 responding 
patients had previously received trastuzumab, and 3 of the 4 patients were previously treated 
with lapatinib. The 2 responding upper GI cancer patients were also HER2-positive, and one 
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was EGFR-negative. These two patients had been treated with trastuzumab-based therapy and 
multiple lines of chemotherapy. The ORRs in patients with HER2-positive breast and upper 
GI cancers were 19% (4/21) and 20% (2/10), respectively.  Figures 1A and 1B demonstrate 
the changes in the sum of longest diameter of target lesions and treatment period in patients 
with breast cancer having at least one evaluable scan (n = 21), and Figures 1C and 1D in 
patients with upper GI cancers (n = 20). Two of the 4 responding patients with breast cancer 
continued on study beyond 40 weeks and the other 2 patients continued beyond 16 weeks. 
The patient with gastro-esophageal junction disease experiencing CR completed a total 
treatment period of 52 weeks and another with PR continued treatment until 39 weeks. 
Five patients with brain metastases from breast cancer were evaluable for radiological 
assessment, and 4 of the 5 patients had brain and/or extra-cranial lesions for assessment by 
RECIST v1.1 (Figure 1B). One of the 4 patients whose only target lesion was a brain 
metastasis achieved PR (Figure 1E) with a sustained response of 7.5 months, and 2 patients 
experienced prolonged SD (> 6 months).  
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4. Discussion 
This was an extended phase I study aiming to assess the safety, tolerability and PK of 
epertinib, as well as to provide a preliminary indication of antitumour activity. As suggested 
by the earlier dose-escalation study of this drug [15], once-daily oral dosing of epertinib at 
800 mg was well-tolerated with predominantly low-grade toxicities including diarrhoea, 
nausea, rash and anorexia; no Grade 3 rash, but Grade 3 diarrhoea observed in 10 patients 
(13.2%) and Grade 2 in 14 out of 76 patients (18.4%). Diarrhoea probably caused by EGFR 
inhibition [17, 18] could be managed by anti-diarrhoeal medication; prophylactic use was not 
allowed in this study.  No patient required discontinuation of epertinib treatment due to 
diarrhoea.  There was no evidence of a drug-related decline in ejection fraction or effects on 
ECG QT interval, despite the known expression of HER2 on cardiac myocytes [19]. As 
reported in the dose-escalation study [15], elevation of blood bilirubin of any grade was 
observed in 30% of patients in the expansion phase but this was not associated with evidence 
of other hepatic or hematologic abnormalities.  Epertinib is known to inhibit the conjugating 
enzyme UGT1A1 in vitro with an IC50 value of 3.7 µmol/L, but not the multidrug resistance 
protein 2 (MRP2) involved in conjugated bilirubin transport. The elevated bilirubin was 
predominantly associated with unconjugated bilirubin in patients measured. Therefore, it is 
considered that the frequent elevation of total blood bilirubin in epertinib-treated patients 
arises from inhibition of UGT1A1-mediated bilirubin conjugation.   
PK parameters of epertinib at 800 mg once-daily were consistent with those reported 
previously [15]. The trough concentrations of epertinib at steady-state markedly exceeded 
those that were seen to inhibit EGFR and HER2 in vitro [14], and the t1/2 was consistent with 
the currently recommended daily dosing schedule. The active dealkylated and lactam 
metabolites which were identified in human but not in mouse have similar activity to that of 
the parent compound against HER2 and EGFR kinase; the IC50 values of the dealkylated and 
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lactam metabolites are known to be 1.24 nmol/L and 2.32 nmol/L for EGFR and 6.31 nmol/L 
and 18.89 nmol/L for HER2, respectively, which are almost equivalent to or lower than those 
for epertinib.  However, the plasma concentration of these metabolites accounted for only 5-
7% and 6-8% of the parent epertinib on a molecular basis, respectively, suggesting that the 
contribution of these metabolites to efficacy is modest.  
In this study, PRs were reported in five patients with breast or upper GI cancers who 
had been previously treated with HER2-targeting drugs, and one CR in another gastro-
esophageal junction cancer patient previously treated with trastuzumab combination.  The 
response rate in patients with HER2-positive breast cancer was 19.0%, which compares 
favorably with 6.9% for lapatinib monotherapy and 10.3% for lapatinib plus trastuzumab for 
HER2-positive breast cancer [20]. Interestingly, we observed one PR and 2 long SDs among 
5 patients with intracranial disease, which is of particular relevance for this challenging 
clinical scenario. Of the 24 upper GI cancer patients evaluable for response, 10 patients were 
HER2-positive and the other 14 patients were HER2-negative. Two of the 10 patients 
(20.0%) with HER2-positive upper GI cancer responded. For HER2-positive upper GI cancer, 
trastuzumab is combined with chemotherapy as a standard second-line therapy, with response 
rates reported to be 37.0% (17/46) in trastuzumab-naïve patients [21] and 9.3% (3/32) in 
trastuzumab-refractory patients [22]. These preliminary data on the activity of epertinib in 
HER2-positive upper GI cancer are promising and warrant further evaluation.  
All the patients with head and neck and renal cancers included in this trial were EGFR-
positive but HER2-negative, and no response was observed in these cancers. Overall, none of 
the 31 patients with HER2-negative cancers enrolled in the expansion phase study responded. 
In the earlier dose-escalation, 18.2% (4/22) of patients whose tumours were HER2-negative 
and EGFR-positive responded, including 3 PRs in upper GI cancer and 1 PR in renal cancer, 
but the response was lower than the 30.0% (3/10) observed in patients with HER2-positive 
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cancers. Combining the data from the dose-escalation and expansion phases suggests that 
HER2-positive status is a better predictive marker for the activity of epertinib than EGFR 
over-expression, although EGFR inhibition may also contribute in part to the efficacy of 
epertinib. Additional pan-erbB inhibitors have been studied in breast cancer patients selected 
for HER2-positivity [23, 24]. 
 In conclusion, continuous once-daily dosing with oral epertinib is well tolerated, and 
shows encouraging signs of antitumour activity particularly in patients with HER2-positive 
breast cancer with or without brain metastasis, even after previous treatment with HER2-
targeted therapies, and also in patients with HER2-positive upper GI cancer. Based on these 
findings, a phase 1/2 study of epertinib in combination with trastuzumab, or with trastuzumab 
plus chemotherapy, was initiated in patients with HER2-positive breast cancer, including 
those with brain metastases.    
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Figure legend 
Figure 1 
Antitumour activity. Response in target lesions (A and C), and duration of response and 
treatment exposure (B and D), in the patients with breast (A and B, n = 21) and upper GI 
cancers (C and D, n = 20), according to HER2 and EGFR status. Partial response in a 43-
year-old patient with brain metastases from HER2-positive breast cancer who received 
epertinib monotherapy at 800 mg (E). This patient, who had previously been treated with 
HER2-based therapies including trastuzumab, lapatinib and capecitabine, had a target lesion 
in the brain for evaluation of tumour response according to RECIST version 1.1. The 
response was observed at 16 weeks and continued until 40 weeks.  
BM: Patients with brain metastases. a Not evaluated by central review but HER2-positive by 
local assessment.   
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promising antitumour activity in patients with heavily pretreated HER2-positive breast and 
upper GI cancer, including those with brain metastases.  
EudraCT Number: 2009-017817-31 
Keywords: Epertinib, S-222611, EGFR, HER2, tyrosine kinase inhibitor 
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1. Introduction 
 Human epidermal growth factor receptor 2 (HER2) is known to be overexpressed in 
approximately 25% of breast cancers and around 20% of gastric cancers, and is associated 
with poor clinical outcome [1, 2].  Trastuzumab, a monoclonal antibody that binds to the 
extracellular domain of HER2, has been established for HER2-positive breast cancer 
treatment in the metastatic and early settings, and for HER2-positive metastatic gastric cancer 
treatment [3-5].  However, in metastatic breast cancer response rates to trastuzumab are only 
15% as monotherapy and 49% in combination with paclitaxel [6, 7].  Also, eventually 
resistance develops in responding patients, and a significant incidence of cardiac toxicity 
particularly in patients previously exposed to anthracyclines has been reported [8].  Several 
aditional anti-HER2 agents, including lapatinib, neratinib, pertuzumab and ado-trastuzumab 
emtansine (T-DM1), are approved, but efficacy is still not completely satisfactory despite 
overall survival improvement with T-DM1 and pertuzumab [3, 9-13].  Therefore, there 
remains an unmet need for HER2 inhibitors that are effective and well tolerated with chronic 
administration.   
Epertinib (S-222611, Shionogi & Co. Ltd, Osaka, Japan) is an orally active, reversible, 
selective and potent inhibitor of epidermal growth factor receptor (EGFR), HER2 and HER4 
kinases. Compared with lapatinib, which has a similar mechanism of action, in mouse 
xenograft models epertinib showed more prolonged inhibition of EGFR and HER2 
phosphorylation in vitro, and 4-6 fold greater antitumour activity [14].  Superior survival was 
also observed in a brain metastasis model of breast cancer, with good penetration of the blood 
brain barrier [14].  
We previously performed a phase I dose-escalation study in 33 patients with solid 
tumours expressing EGFR and/or HER2 [15]. Oral epertinib was well tolerated at doses 
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ranging from 100 mg to 1600 mg, and a maximum tolerated dose was not reached. Drug 
exposure increased dose-proportionally over a range from 100 mg to 800 mg and tumour 
responses were observed across a range of doses. Based on these results, a dose of 800 mg 
was selected for further study. We now report an extended study of epertinib in patients with 
advanced solid tumours over-expressing EGFR and/or HER2. 
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2. Methods 
2.1. Patients 
Eligible patients were ≥ 18 years old with histologically and/or cytologically confirmed 
EGFR and/or HER2-positive adenocarcinoma of the breast, with or without cerebral 
metastases; adenocarcinoma of the stomach, gastro-esophageal junction or esophagus; renal 
cell carcinoma; or squamous cell carcinoma of the head and neck, that had progressed 
following treatment with approved therapies, or for which no standard therapy was available. 
The EGFR and HER2 expression were assessed at central or local laboratories using fresh 
tumour biopsy obtained at screening or archival tissue for confirmation of the eligibility, 
while the EGFR/HER2 status assessed by the central review was used for evaluation of 
efficacy. Eligible patients were required to have Eastern Cooperative Oncology Group 
(ECOG) performance status 0 or 1, and adequate hematological, renal, hepatic and left 
ventricular function (≥ 50%). Patients with brain metastasis from HER2-positive breast 
cancer were allowed to be enrolled in this study based on the evidence showing that superior 
efficacy in suppressing tumour growth of brain metastases compared to lapatinib in an 
intracranial implantation mouse model [14]. The study was approved after review by the 
relevant regulatory and independent ethics committees (EudraCT Number: 2009-017817-31), 
and was conducted in accordance with the Declaration of Helsinki and International 
Conference on Harmonization Good Clinical Practice. All patients provided written informed 
consent before enrollment.  
 
2.2. Study design 
Epertinib was initially administered as a single dose on Day 1, followed by continuous daily 
dosing from Day 8 to Day 28. Patients received continuous dosing with epertinib in 28-day 
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cycles until disease progression, intolerable toxicity or withdrawal of consent. The primary 
objective was to assess further the safety and tolerability of epertinib. Secondary objectives 
included pharmacokinetics (PK) and an extended assessment of efficacy. 
 
2.3. Safety assessment 
Adverse events (AEs) were monitored and clinical laboratory parameters, weight, vital signs, 
12 lead ECGs, physical and ophthalmic examinations, cardiac function including left 
ventricular ejection fraction, and ECOG performance status were assessed at baseline and 
throughout the study, and lead II continuous monitoring was carried out for 8 hours post-
dosing on Day 1. All AEs were coded using National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 
 
2.4. Pharmacokinetic analysis 
Blood samples for the measurement of plasma concentrations of epertinib and its active de-
alkylated and lactam metabolites were taken at the following times during treatment: Day 1 
(pre-dose, 2, 4, 6, and 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 (48 hours 
post-dose), Day 5 (96 hours post-dose), Days 8, 15, 22 and 29 (pre-dose). Samples were also 
taken before dosing on Days 15 and 29 of the first two cycles of Part B.  Plasma 
concentration measurement and calculation of the PK parameters of epertinib and its active 
metabolites were performed in the same manner as described in our previous report [15]. 
 
2.5. Tumour evaluation  
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Tumour response was assessed every 8 weeks according to Response Evaluation Criteria in 
Solid Tumours (RECIST) Version 1.1 [16].  Patients who had at least one additional scan 
after baseline, and patients who had no additional scan but discontinued due to clinical 
disease progression, were considered evaluable for response.  
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3. Results 
3.1. Safety and tolerability 
 Between July 2010 and January 2014, a total of 76 patients with breast (n = 27), upper 
GI (n = 30), head and neck (n = 12) and renal cell carcinoma (n = 7) were enrolled at 9 sites 
in the United Kingdom and France. Patient demographics and baseline characteristics are 
summarised in Table 1. As shown in patient disposition (Figure S1), 14 patients (7 patients in 
Part A and 7 patients in Part B) discontinued due to treatment-emergent adverse events 
(TEAEs). Only 2 patients discontinued due to TEAEs (nausea and vomiting, and bilirubin 
elevation) that were considered drug-related. Disease progression accounted for all other 
discontinuations except for one patient who was withdrawn due to deteriorating quality of life.  
Table 2 summarises all TEAEs of any grade occurring in at least 10% of patients, and all 
Grade 3 or higher TEAEs. There were no treatment-related deaths. Epertinib at 800 mg once 
daily was well tolerated by most patients, with 21.1% (16/76) of patients requiring dose 
reduction. The majority of AEs were Grade 1 or 2 in intensity, and no significant 
hematological or biochemical toxicity was observed. Overall, the most frequently reported 
AEs were diarrhoea, nausea, rash and anorexia. Diarrhoea was generally self-limiting or 
effectively controlled with loperamide; in 10 (13.2%) patients it was Grade 3. Nausea was 
almost always Grade 1 or 2 and was effectively managed with antiemetics and dose 
interruptions.  Rash was reported in 32 (42.1%) patients, of which none was more severe than 
Grade 2.  There were no effects on ECG, and no evidence that epertinib treatment affected 
cardiac function. 
Bilirubin elevation was observed in 23 patients (30.3%); this elevation was Grade 3 in 5 
patients (6.6%), and Grade ≤2 in all others. The increase in bilirubin was not associated with 
any symptoms, elevation of liver enzymes or hematologic abnormalities. When the 
10 
 
unconjugated and conjugated bilirubin was measured in 14 of the 23 patients, the elevation 
was predominantly attributable to unconjugated bilirubin. Dose reduction was required due to 
bilirubin elevation in 1 patient (1.3%), and resulted in study discontinuation in one (1.3%) 
other patient. 
 
3.2. Pharmacokinetic analysis. 
The PK parameters after single administration and trough plasma concentrations after 
repeated doses at 800 mg are summarised in Table S1. Epertinib was absorbed with a median 
Tmax of 4.1 hours and geometric mean Cmax of 454 ng/mL following a single oral dose. The 
geometric mean t1/2,z was 33.8 hours and steady-state was achieved within 7 days of 
once-daily dosing. The pharmacologically active dealkylated and lactam metabolites of 
epertinib were rapidly formed, and the exposures (AUC0-inf and Cmax) to these metabolites 
were 5-7% and 6-8% on a molecular basis of the parent epertinib, respectively.  
 
3.3. Clinical response. 
Sixty five of 76 patients were evaluable for tumour response. The tumour responses for each 
cancer are shown in Table S2. Two patients with gastro-esophageal junction tumours had CR 
and PR, and 4 patients with breast cancer experienced PR. The objective response rate (ORR) 
for breast, upper GI, head and neck and renal cell cancers were 16.0% (4/25), 8.3% (2/24), 
0% (0/9) and 0% (0/7), respectively.  As shown in Table 3, all of the 4 responding breast 
cancer patients were HER2-positive, but 2 of them were EGFR-negative. All 4 responding 
patients had previously received trastuzumab, and 3 of the 4 patients were previously treated 
with lapatinib. The 2 responding upper GI cancer patients were also HER2-positive, and one 
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was EGFR-negative. These two patients had been treated with trastuzumab-based therapy and 
multiple lines of chemotherapy. The ORRs in patients with HER2-positive breast and upper 
GI cancers were 19% (4/21) and 20% (2/10), respectively.  Figures 1A and 1B demonstrate 
the changes in the sum of longest diameter of target lesions and treatment period in patients 
with breast cancer having at least one evaluable scan (n = 21), and Figures 1C and 1D in 
patients with upper GI cancers (n = 20). Two of the 4 responding patients with breast cancer 
continued on study beyond 40 weeks and the other 2 patients continued beyond 16 weeks. 
The patient with gastro-esophageal junction disease experiencing CR completed a total 
treatment period of 52 weeks and another with PR continued treatment until 39 weeks. 
Five patients with brain metastases from breast cancer were evaluable for radiological 
assessment, and 4 of the 5 patients had brain and/or extra-cranial lesions for assessment by 
RECIST v1.1 (Figure 1B). One of the 4 patients whose only target lesion was a brain 
metastasis achieved PR (Figure 1E) with a sustained response of 7.5 months, and 2 patients 
experienced prolonged SD (> 6 months).  
  
12 
 
4. Discussion 
This was an extended phase I study aiming to assess the safety, tolerability and PK of 
epertinib, as well as to provide a preliminary indication of antitumour activity. As suggested 
by the earlier dose-escalation study of this drug [15], once-daily oral dosing of epertinib at 
800 mg was well-tolerated with predominantly low-grade toxicities including diarrhoea, 
nausea, rash and anorexia; no Grade 3 rash, but Grade 3 diarrhoea observed in 10 patients 
(13.2%) and Grade 2 in 14 out of 76 patients (18.4%). Diarrhoea probably caused by EGFR 
inhibition [17, 18] could be managed by anti-diarrhoeal medication; prophylactic use was not 
allowed in this study.  No patient required discontinuation of epertinib treatment due to 
diarrhoea.  There was no evidence of a drug-related decline in ejection fraction or effects on 
ECG QT interval, despite the known expression of HER2 on cardiac myocytes [19]. As 
reported in the dose-escalation study [15], elevation of blood bilirubin of any grade was 
observed in 30% of patients in the expansion phase but this was not associated with evidence 
of other hepatic or hematologic abnormalities.  Epertinib is known to inhibit the conjugating 
enzyme UGT1A1 in vitro with an IC50 value of 3.7 µmol/L, but not the multidrug resistance 
protein 2 (MRP2) involved in conjugated bilirubin transport. The elevated bilirubin was 
predominantly associated with unconjugated bilirubin in patients measured. Therefore, it is 
considered that the frequent elevation of total blood bilirubin in epertinib-treated patients 
arises from inhibition of UGT1A1-mediated bilirubin conjugation.   
PK parameters of epertinib at 800 mg once-daily were consistent with those reported 
previously [15]. The trough concentrations of epertinib at steady-state markedly exceeded 
those that were seen to inhibit EGFR and HER2 in vitro [14], and the t1/2 was consistent with 
the currently recommended daily dosing schedule. The active dealkylated and lactam 
metabolites which were identified in human but not in mouse have similar activity to that of 
the parent compound against HER2 and EGFR kinase; the IC50 values of the dealkylated and 
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lactam metabolites are known to be 1.24 nmol/L and 2.32 nmol/L for EGFR and 6.31 nmol/L 
and 18.89 nmol/L for HER2, respectively, which are almost equivalent to or lower than those 
for epertinib.  However, the plasma concentration of these metabolites accounted for only 5-
7% and 6-8% of the parent epertinib on a molecular basis, respectively, suggesting that the 
contribution of these metabolites to efficacy is modest.  
In this study, PRs were reported in five patients with breast or upper GI cancers who 
had been previously treated with HER2-targeting drugs, and one CR in another gastro-
esophageal junction cancer patient previously treated with trastuzumab combination.  The 
response rate in patients with HER2-positive breast cancer was 19.0%, which compares 
favorably with 6.9% for lapatinib monotherapy and 10.3% for lapatinib plus trastuzumab for 
HER2-positive breast cancer [20]. Interestingly, we observed one PR and 2 long SDs among 
5 patients with intracranial disease, which is of particular relevance for this challenging 
clinical scenario. Of the 24 upper GI cancer patients evaluable for response, 10 patients were 
HER2-positive and the other 14 patients were HER2-negative. Two of the 10 patients 
(20.0%) with HER2-positive upper GI cancer responded. For HER2-positive upper GI cancer, 
trastuzumab is combined with chemotherapy as a standard second-line therapy, with response 
rates reported to be 37.0% (17/46) in trastuzumab-naïve patients [21] and 9.3% (3/32) in 
trastuzumab-refractory patients [22]. These preliminary data on the activity of epertinib in 
HER2-positive upper GI cancer are promising and warrant further evaluation.  
All the patients with head and neck and renal cancers included in this trial were EGFR-
positive but HER2-negative, and no response was observed in these cancers. Overall, none of 
the 31 patients with HER2-negative cancers enrolled in the expansion phase study responded. 
In the earlier dose-escalation, 18.2% (4/22) of patients whose tumours were HER2-negative 
and EGFR-positive responded, including 3 PRs in upper GI cancer and 1 PR in renal cancer, 
but the response was lower than the 30.0% (3/10) observed in patients with HER2-positive 
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cancers. Combining the data from the dose-escalation and expansion phases suggests that 
HER2-positive status is a better predictive marker for the activity of epertinib than EGFR 
over-expression, although EGFR inhibition may also contribute in part to the efficacy of 
epertinib. Additional pan-erbB inhibitors have been studied in breast cancer patients selected 
for HER2-positivity [23, 24]. 
 In conclusion, continuous once-daily dosing with oral epertinib is well tolerated, and 
shows encouraging signs of antitumour activity particularly in patients with HER2-positive 
breast cancer with or without brain metastasis, even after previous treatment with HER2-
targeted therapies, and also in patients with HER2-positive upper GI cancer. Based on these 
findings, a phase 1/2 study of epertinib in combination with trastuzumab, or with trastuzumab 
plus chemotherapy, was initiated in patients with HER2-positive breast cancer, including 
those with brain metastases.    
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Figure legend 
Figure 1 
Antitumour activity. Response in target lesions (A and C), and duration of response and 
treatment exposure (B and D), in the patients with breast (A and B, n = 21) and upper GI 
cancers (C and D, n = 20), according to HER2 and EGFR status. Partial response in a 43-
year-old patient with brain metastases from HER2-positive breast cancer who received 
epertinib monotherapy at 800 mg (E). This patient, who had previously been treated with 
HER2-based therapies including trastuzumab, lapatinib and capecitabine, had a target lesion 
in the brain for evaluation of tumour response according to RECIST version 1.1. The 
response was observed at 16 weeks and continued until 40 weeks.  
BM: Patients with brain metastases. a Not evaluated by central review but HER2-positive by 
local assessment.   
 
Table 1. Patient demographics and baseline characteristics (N = 76) 
Characteristics  
Age (years)  
Mean 59.8 
Range 31-81 
Sex  
Female 33 (43.4%) 
Male 43 (56.6%) 
Primary cancer  
Upper gastrointestinal adenocarcinoma 30 (39.5%) 
Breast adenocarcinoma 27 (35.5%) 
Head & neck squamous cell carcinoma 12 (15.8%) 
Renal cell carcinoma 7 (9.2%) 
ECOG PS at screening  
0 24 (31.6%) 
1 51 (67.1%) 
2 1 (1.3%) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status. 
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Table 3. Tumour response by HER2 and EGFR status in patients with breast, upper GI, head 
and neck and renal cancers  
 
HER2 EGFR 
Number of patients (%) with tumour response 
Breast 
N = 25 
Upper GIa 
N = 24 
H&N 
N = 9 
Renal 
N = 7 
Total 
N = 65 
Positive Positive 2/9 (22.2) 1/8 (12.5) 0/1 (0) 0/0 (0) 3/18 (16.7) 
Positive Negative 2/12 (16.6) 1/2 (50.0) 0/0 (0) 0/0 (0) 3/14 (21.4) 
Negative Positive 0/1 (0) 0/13 (0) 0/8 (0) 0/7 (0) 0/29 (0) 
Negativeb Negative 0/1 (0) 0/1 (0) 0/0 (0) 0/0 (0) 0/2 (0) 
Not evaluablec 0/2 (0) 0/0 (0) 0/0 (0) 0/0 (0) 0/2 (0) 
 
a Upper GI includes adenocarcinoma of stomach, gastro-esophageal junction and esophagus. 
b Results shown are those obtained at central review. 2 patients were enrolled based on 
HER2-positivity assessed by the local laboratory at the treating site, but in each case both 
HER2 and EGFR were negative on central review.  
c 2 patients’ tumours which had HER2-positive status from the local assessment were not 
evaluable at the central laboratory.  
 
Table 3
Supplementary Table S1. Geometric mean (Geometric CV %) pharmacokinetic parameters of epertinib and its pharmacologically active 
dealkylated and lactam metabolites after single oral administration of 800 mg on Day 1 and mean trough plasma concentrations on Days 
15, 22 and 29 after repeated administration of 800 mg started on Day 8 
 
 
 Pharmacokinetic parameters 
after single dose administration (Day 1) 
Trough plasma concentrations  
after repeated dose administration 
 n 
Cmax  
(ng/mL) 
Tmax  
(h) 
AUC0-inf  
(ng·h/mL) 
CL/F  
(L/h) 
Vz/F  
(L) 
t1/2,z  
(h) 
Conc. 
(ng/mL) 
Day 15 
Conc. 
(ng/mL) 
Day 22 
Conc. 
(ng/mL) 
Day 29 
Epertinib 
76 
454 
 (53.3) 
4.06 
(1.98-12.13) 
11100 
(45.0)a 
72.2 
(44.9)a 
3510 
(47.6)a 
33.8 
(17.4)c 
331 
(124)d 
320 
(125)f 
330 
(137)g 
Dealkylated 
23.3 
 (50.8) 
6.00 
(2.12-24.17) 
685 
(47.1)a 
- - 
48.6 
(21.8)a 
35.4 
(16.8)d 
36.2 
(16.5)f 
37.3 
(15.1)g 
Lactam 
35.8 
 (51.5) 
5.98 
(2.00-24.17) 
770 
(41.6)b 
- - 
30.6 
(24.0)b 
16.7 
(8.42)e 
15.8 
(6.62)f 
15.3 
(7.52)g 
Geometric Mean (Geometric Coefficient of Variation [CV] %) values except Tmax for which median and range are shown for 
pharmacokinetic parameters. Mean (SD) values are shown for trough plasma concentrations.  
Abbreviations: Cmax, maximum plasma concentration; Tmax, time to Cmax; AUC0-inf, area under plasma concentration versus time curve 
from time zero extrapolated to infinity; CL/F, apparent total body clearance; Vz/F, apparent volume of distribution and t1/2,z, terminal 
half-life; Conc. concentration. 
a N = 73. b N = 72. c N = 74. d N = 58. e N = 57. f N = 56. g N = 51. 
Supplementary Table S1 (online publication only)
 
 
Supplementary Table S2. Tumour response in patients with breast, upper GI, head and neck 
and renal cancers  
 Breast Upper GIa H&N Renal Total 
Overall response rate 
N (%) 
4/25 
(16.0) 
2/24 
(8.3) 
0/9 
(0) 
0/7 
 (0) 
6/65 
(9.2) 
CR 0 1 0 0 1 
PR 4 1 0 0 5 
SD 12 11 6 3 32 
PD 9 11 3 4 27 
 
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease; GI, gastrointestinal; H&N, head and neck 
aUpper GI includes adenocarcinoma of stomach, gastro-esophageal junction and esophagus 
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Table 2.  Treatment-emergent adverse events occurring in ≥10% of patients 
 Epertinib 800 mg (N = 76) 
N (%) 
 All grades 
 N (%) 
Grade ≥3a 
N (%) Diarrhoea 59 (77.6) 10 (13.2) 
Nausea 37 (48.7) 3 (3.9) 
Rash 32 (42.1) - 
Decreased appetite 31 (40.8) 4 (5.3) 
Fatigue 30 (39.5) 7 (9.2) 
Vomiting 29 (38.2) 3 (3.9) 
Bilirubin elevation 23 (30.3) 5 (6.6) 
Constipation 20 (26.3) - 
Headache 19 (25.0) - 
Anaemia 15 (19.7) 6 (7.8) 
Abdominal pain 13 (17.1) - 
Dry skin 13 (17.1) - 
Cough 13 (17.1) - 
Asthenia 11 (14.5) 3 (3.9) 
Nasopharyngitis 10 (13.2) - 
Pruritus 10 (13.2) - 
Pyrexia 10 (13.2) - 
Weight loss 9 (11.8) - 
Oedema peripheral 9 (11.8) - 
Dyspnoea 9 (11.8) 4 (5.3) 
Abdominal pain upper 8 (10.5) - 
aThere were no Grade 4 or 5 treatment-related adverse events. 
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